BCAX

Bicara Therapeutics went public in 2024, listing on Nasdaq under the ticker BCAX. Over the past year, the stock price increased by approximately 90.03% to $116.86, but in the past month, it decreased by 7.89% to $12.45. In August 2026, the company reported a second-quarter 2026 loss of $0.82 per share, causing a 16.7% drop in shares to $23.11 due to concerns about rising expenses and a long commercialization timeline, though it held approximately $497 million in cash expected to fund operations into the first half of 2029. Several analysts have initiated or reiterated positive coverage on BCAX; BMO Capital initiated coverage with an Outperform rating and a $35 price target, while BTIG and Morgan Stanley raised their price targets to $39, and Mizuho increased its target to $20. Analysts have raised the fair value estimate for Bicara Therapeutics to $33.50 from $30.50, citing a stronger outlook for ficerafusp alfa and a solid cash position. The pivotal FORTIFI-HN01 interim analysis, expected in mid-2027, is identified as a key value inflection point for the stock.